NNI-351

NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.